Remove 2025 Remove Genetics and mental health Remove Sleep and mental health
article thumbnail

The Psychiatric Pipeline in Review: Quarter 2, 2025

Psychiatric Times

The second quarter of 2025 saw some huge successes and fails in the psychiatric treatment pipeline. What percentage of 2025 Q2 psychiatric pipeline news was positive vs negative? Together, they will aim to bring innovative mental health treatments to patients in need. Learn more in this exclusive article.

article thumbnail

Eyes, Ears, and Emotion: Techniques to Tackle Diagnosing Bipolar Disorder

Psychiatric Times

Emerging research on RNA biomarkers, AI applications, and genetic mutations shows promise for developing new diagnostic tools for bipolar disorder. However, new research focuses in on RNA biomarkers, RNA editing, artificial intelligence applications, genetic mutations in thyroid pathways, and ceramide-based metabolite profiling.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Presenting Our August Theme: ADHD

Psychiatric Times

Do you have practice tips to offer your fellow mental health clinicians? Accessed August 1, 2025. children, highlighting its significant prevalence and rising diagnosis rates. children, highlighting its significant prevalence and rising diagnosis rates. What comorbidities do you often see with ADHD in your practice?

article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Health care professionals should monitor the child’s growth and development and provide necessary interventions to mitigate weight loss.”

article thumbnail

PTSD In Review: Treatment Insights

Psychiatric Times

Genetic links between PTSD and migraines suggest shared pathways, with genes DAPK2 and TM6SF2 implicated in both disorders. Lightfield Studios/Adobe Stock On Friday, July 18, 2025, the FDA Advisory Committee voted against recommending brexpiprazole plus sertraline for the treatment of posttraumatic stress disorder (PTSD).

article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

NRx is targeting suicidal depression and PTSD with NRX-100, anticipating an FDA decision by the end of 2025. The company continues to anticipate an FDA decision on NRX-100 by the end of 2025. The CNPV program, introduced by FDA Commissioner Marty Makary, aims to reduce review times to 1-2 months for eligible applications.

article thumbnail

ADHD Treatment Options

Psychiatric Times

Related Videos Related Content Advertisement June 17th 2025 ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment David N. Subscribe Now!